The Strategy of Immunologic Control of HIV-1 with Structured Treatment Interruptions (STIs)

Title: The Strategy of Immunologic Control of HIV-1 with Structured Treatment Interruptions (STIs)

Volume: 1 Issue: 1

Author(s): Ronald B. Moss, Fred C. Jensen, Dennis J. Carlo and Mark. R. Wallace

Affiliation:

Keywords: Structured Treatment Interruptions STIs, antiretroviral therapy HAART

Abstract: Structured treatment interruptions (STIs) have evolved as an experimental approach of interrupting highly active antiretroviral therapy (HAART) similar to cycles of cancer chemotherapy in order to develop immune control of HIV-1. There are multiple, on-going clinical trials examining interruptions in antiviral therapy with and without immune-based therapies. If successful in developing immune control, STIs may be clinically useful but require large scale clinical trials to prove their utility and safety.

Cite this article as:

Moss B. Ronald, Jensen C. Fred, Carlo J. Dennis and Wallace R. Mark., The Strategy of Immunologic Control of HIV-1 with Structured Treatment Interruptions (STIs), Current Drug Targets - Infectious Disorders 2001; 1 (1) . https://dx.doi.org/10.2174/1568005013343236

DOI https://dx.doi.org/10.2174/1568005013343236	Print ISSN 1568-0053
Publisher Name Bentham Science Publisher	Online ISSN 1875-5852